STERIALS

A specialty pharmaceutical company focused on developing and commercializing innovative therapeutics for medically supervised use. Its lead product candidate, Niyad (nafamostat mesylate), is a lyophilized formulation that has the potential to significantly improve the standard of care for patients undergoing renal replacement therapy (RRT) as the first FDA-approved regional anticoagulant for use in extracorporeal circuits.